Search Results - "Hill, Michael P"

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease by Kobylecki, Christopher, Hill, Michael P., Crossman, Alan R., Ravenscroft, Paula

“…L‐Dopa‐induced dyskinesia in patients with Parkinson's disease can be alleviated by amantadine, an antagonist at N‐methyl‐D‐aspartate glutamate receptors. The…”
Get full text

Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit by Eskow Jaunarajs, Karen L., Standaert, David G., Viegas, Tacey X., Bentley, Michael D., Fang, Zhihao, Dizman, Bekir, Yoon, Kunsang, Weimer, Rebecca, Ravenscroft, Paula, Johnston, Tom H., Hill, Michael P., Brotchie, Jonathan M., Moreadith, Randall W.

“…ABSTRACT Currently available dopaminergic drugs such as levodopa and dopamine (DA) receptor agonists impart considerable improvement in Parkinson's disease…”
Get full text

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials by Meissner, Wassilios, Hill, Michael P., Tison, François, Gross, Christian E., Bezard, Erwan

“…Parkinson's disease (PD) is a progressive neurodegenerative disorder. Although therapies that treat the symptoms of the disease have proven efficacy,…”
Get full text

Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease by Hill, Michael P, Ravenscroft, Paula, Bezard, Erwan, Crossman, Alan R, Brotchie, Jonathan M, Michel, Anne, Grimée, Renee, Klitgaard, Henrik

“…Levetiracetam (LEV) (Keppra; UCB Pharma, Brussels, Belgium) has recently been reported to have antidyskinetic activity against levodopa (L-DOPA)-induced…”
Get more information

Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's Disease by Howson, Patrick A, Johnston, Tom H, Ravenscroft, Paula, Hill, Michael P, Su, Jin, Brotchie, Jonathan M, Koprich, James B

“…Disease modification in Parkinson's disease (PD) is an unmet medical need. In the current study, we evaluated trehalose, a safe and well-tolerated disaccharide…”
Get more information

A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease by Schneider, Jay S., Marshall, Courtney A., Keibel, Lauren, Snyder, Nathaniel W., Hill, Michael P., Brotchie, Jonathan M., Johnston, Tom H., Waterhouse, Barry D., Kortagere, Sandhya

“…Mild cognitive impairment is present in a number of neurodegenerative disorders including Parkinson's disease (PD). Mild cognitive impairment in PD (PD-MCI)…”
Get full text

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset by Hill, Michael P., Bezard, Erwan, McGuire, Steven G., Crossman, Alan R., Brotchie, Jonathan M., Michel, Ann, Grimée, Renee, Klitgaard, Henrik

“…Long‐term dopamine replacement therapy of Parkinson's disease leads to the occurrence of dyskinesias. Altered firing patterns of neurons of the internal globus…”
Get full text

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease by Johnston, Tom H., Versi, Eboo, Howson, Patrick A., Ravenscroft, Paula, Fox, Susan H., Hill, Michael P., Reidenberg, Bruce E., Corey, Ronald, Brotchie, Jonathan M.

“…L-DOPA-induced dyskinesia (LID) remains a significant problem in the management of Parkinson's disease (PD). In rodent and macaque models of PD, delta opioid…”
Get full text

TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque by Johnston, Tom H., Huot, Philippe, Fox, Susan H., Koprich, James B., Szeliga, Kendall T., James, John W., Graef, John D., Letchworth, Sharon R., Jordan, Kristen G., Hill, Michael P., Brotchie, Jonathan M.

“…Long-term l-DOPA treatment for Parkinson's disease (PD) is limited by motor complications, particularly l-DOPA-induced dyskinesia (LID). A therapy with the…”
Get full text

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque by Huot, Philippe, Johnston, Tom H., Snoeren, Tessa, Koprich, James B., Hill, Michael P., Fox, Susan H., Brotchie, Jonathan M.

“…L‐3,4‐dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia is a complication of dopaminergic treatment in Parkinson's disease. Lowering the L‐DOPA dose reduces…”
Get full text

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque by Bezard, Erwan, Hill, Michael P., Crossman, Alan R., Brotchie, Jonathan M., Michel, Anne, Grimée, Renee, Klitgaard, Henrik

“…l-3,4 dihydroxyphenylalanine (levodopa)-induced dyskinesia in Parkinson's disease patients is characterized by a mixture of chorea and dystonia…”
Get full text

Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease by Zachrisson, Olof, Zhao, Ming, Andersson, Annica, Dannaeus, Karin, Häggblad, Johan, Isacson, Ruben, Nielsen, Elisabet, Patrone, Cesare, Rönnholm, Harriet, Wikstrom, Lilian, Delfani, Kristofer, McCormack, Alison L, Palmer, Theo, Di Monte, Donato A, Hill, Michael P, Janson Lang, Ann Marie, Haegerstrand, Anders

“…Parkinson's disease is characterized by motor deficits caused by loss of midbrain dopaminergic neurons. Neurotrophic factors and cell transplantation have…”
Get more information

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors by Hill, Michael P., Ravenscroft, Paula, McGuire, Steven G., Brotchie, Jonathan M., Crossman, Alan R., Rochat, Catherine, Millan, Mark J.

“…L‐dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D3/D2 receptor agonists such as the novel agent…”
Get full text

Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets by Hill, Michael P, Brotchie, Jonathan M, Crossman, Alan R, Bezard, Erwan, Michel, Anne, Grimée, Renee, Klitgaard, Henrik

“…Levetiracetam (LEV; Keppra, UCB Pharma) has been shown to reduce established l-3,4 dihydroxyphenylalanine (l-dopa)-induced dyskinesia. This study investigated…”
Get full text

Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes by East, Stephen J., Hill, Michael P., Brotchie, Jonathan M.

“…A striatal synaptosomal preparation was used to assess the action of metabotropic glutamate receptor (mGlu receptor) agonists on 4-aminopyridine (2…”
Get full text

Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism by Hughes, Neill R., McKnight, Alexander T., Woodruff, Geoffrey N., Hill, Michael P., Crossman, Alan R., Brotchie, Jonthan M.

“…Excessive glutamate transmission in the basal ganglia is a major factor in the neural mechanisms underlying parkinsonian akinesia. Activation of K opioid…”
Get full text

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease by Marzo, Vincenzo, Hill, Michael P., Bisogno, Tiziana, Crossman, Alan R., Brotchie, Jonathan M.

“…In recent years, cannabinoid receptors and their endogenous ligands (endocannabinoids) have been identified within the brain. The high density of CB1…”
Get full text

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease by DI MARZO, V.

Get full text

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydrop yridine-lesioned macaque by Huot, Philippe, Johnston, Tom H, Snoeren, Tessa, Koprich, James B, Hill, Michael P, Fox, Susan H, Brotchie, Jonathan M

“…L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia is a complication of dopaminergic treatment in Parkinson's disease. Lowering the L-DOPA dose reduces…”
Get full text

Antiparkinsonian effects of the novel D 3 /D 2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D 2 , not D 3 , dopamine receptors by Hill, Michael P., Ravenscroft, Paula, McGuire, Steven G., Brotchie, Jonathan M., Crossman, Alan R., Rochat, Catherine, Millan, Mark J.

“…Abstract L ‐dopa remains the most common treatment for Parkinson's disease. However, there is considerable interest in D 3 /D 2 receptor agonists such as the…”
Get full text